Dark

Check out our Level2View

PPCB
Propanc Biopharma, Inc. Common Stock
stock NASDAQ

Market Open

Jun 11, 2026 1:32:23 PM EDT

2.76USD+104.444%(+1.41)155,680,047

2.75Bid 3.14Ask 0.39Spread

Pre-market

Jun 11, 2026 9:29:58 AM EDT

3.23USD+139.259%(+1.88)5,297,495

After-hours

Jun 10, 2026 4:00:30 PM EDT

1.35USD-4.594%(-0.06)0

OverviewHistoricalExchangesShortsNews

Dec 21, 2021

09:00AM EST Propanc Biopharma Demonstrates Significant Effects of Proenzyme Therapy on the Tumor Microenvironment Business Wire

Dec 14, 2021

09:00AM EST Propanc Biopharma Enters into $5 Million Equity Purchase Facility with Dutchess Capital Growth Fund LP Business Wire

Nov 3, 2021

09:00AM EDT Propanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US Based R&D Operating Subsidiary, Cellmed Bio LLC, in New Jersey Business Wire

May 17, 2021

09:00AM EDT Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes Business Wire

Mar 25, 2021

09:00AM EDT Propanc Biopharma Provides Upcoming Milestones Business Wire

Mar 3, 2021

09:00AM EST Propanc Biopharma Provides A Shareholder Update for 2021 Business Wire

Feb 15, 2021

09:00AM EST Professor Juan Marchal Believes Propanc Biopharma's Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients Business Wire

Jan 28, 2021

09:00AM EST Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment Business Wire

Jan 18, 2021

08:31AM EST Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients Business Wire

Jan 11, 2021

08:30AM EST Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers Business Wire

Dec 30, 2020

08:30AM EST Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market Business Wire

Dec 21, 2020

08:30AM EST Propanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent Office Business Wire

Jul 28, 2020

08:30AM EDT Propanc Biopharma Receives Investment from Institutional Investor Business Wire

Share